Haemonetics Corporation
HAE
$57.17
$0.280.49%
NYSE
| 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 130.07M | 123.81M | 114.89M | 117.56M | 126.57M |
| Total Depreciation and Amortization | 106.42M | 100.92M | 94.86M | 88.62M | 84.93M |
| Total Amortization of Deferred Charges | 9.38M | 9.38M | 9.38M | 9.38M | 9.37M |
| Total Other Non-Cash Items | 13.75M | 17.71M | 21.69M | 40.90M | 55.81M |
| Change in Net Operating Assets | -130.36M | -166.89M | -105.58M | -74.70M | -79.41M |
| Cash from Operations | 129.25M | 84.94M | 135.24M | 181.75M | 197.28M |
| Capital Expenditure | -45.97M | -53.82M | -66.50M | -66.30M | -68.53M |
| Sale of Property, Plant, and Equipment | 21.35M | 21.44M | 21.77M | 1.81M | -4.83M |
| Cash Acquisitions | -150.91M | -394.76M | -393.00M | -243.85M | -243.85M |
| Divestitures | 1.50M | 1.50M | 1.50M | 1.50M | 0.00 |
| Other Investing Activities | -18.97M | -18.92M | -10.09M | -15.55M | -10.13M |
| Cash from Investing | -192.99M | -444.56M | -446.33M | -322.39M | -327.34M |
| Total Debt Issued | 950.00M | 1.06B | 1.06B | 110.00M | 110.00M |
| Total Debt Repaid | -652.83M | -654.76M | -658.26M | -72.25M | -10.50M |
| Issuance of Common Stock | 8.30M | 7.68M | 8.12M | 7.21M | 7.27M |
| Repurchase of Common Stock | -85.24M | -84.84M | -14.15M | -5.89M | -5.89M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -23.47M | -23.26M | -23.26M | -922.00K | -826.00K |
| Cash from Financing | 196.77M | 304.82M | 372.45M | 38.16M | 100.06M |
| Foreign Exchange rate Adjustments | -6.16M | 3.08M | -2.66M | -3.19M | -22.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 126.87M | -51.72M | 58.71M | -105.67M | -30.02M |